

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Form 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2018

**FENNEC PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

**001-32295**

(Commission File Number)

**British Columbia, Canada**  
(State or other jurisdiction of  
incorporation)

**20-0442384**  
(I.R.S. Employer Identification No.)

**PO Box 13628, 68 TW Alexander Drive,**  
**Research Triangle Park, NC**  
(Address of principal executive offices)

**27709**  
(Zip Code)

**Registrant's telephone number, including area code: (919) 636-4530**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 7, 2018, Fennec Pharmaceuticals Inc. (the “Company”) held an annual and special meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:

1. The following five (5) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:

Name of Nominee	Votes For	Votes Withheld	Broker Non-Votes
Dr. Khalid Islam	9,766,926	795,329	2,451,220
Adrian Haigh	9,767,181	795,074	2,451,220
Chris A. Rallis	9,765,833	796,422	2,451,220
Marco Brughera	10,558,689	3,566	2,451,220
Rostislav Raykov	10,559,584	2,671	2,451,220

2. The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:

Votes For	12,999,856
Votes Withheld	13,619
Abstentions	0
Broker Non-Votes	0

3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:

Votes For	10,293,495
Votes Against	268,760
Abstentions	0
Broker Non-Votes	2,451,220

4. The resolution to vote for the approval of extension of executive officer options was approved based on the following vote:

Votes For	9,745,451
Votes Against	816,804
Abstentions	0
Broker Non-Votes	2,451,220

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FENNEC PHARMACEUTICALS INC.

Date June 11, 2017

By: /s/ Rostislav Raykov  
Rostislav Raykov  
Chief Executive Officer